TSXgroup

February 1, 2008

Protox Therapeutics Inc. (the "Company") - An application has been granted for the original listing in the Industrial category of 86,323,858 common shares of the Company, of which 68,505,433 common shares are issued and outstanding, and 17,818,425 common shares are reserved for issuance.

The common shares of the Company will be listed and posted for trading at the opening on Monday, February 4, 2008.

The Company is subject to the reporting requirements of Section 501 of the TSX Company Manual.

Common Shares:
Stock Symbol: "PRX"
CUSIP: 74373H 10 6
Trading Currency: CDN

Temporary Market Maker: Research Capital Corporation

Other Markets: The common shares of the Company have been listed on TSX Venture Exchange since July 14, 2004. The common shares will be delisted from TSX Venture Exchange on February 4, 2008, upon commencement of trading on TSX.

Head Office Address: 1210 - 885 West Georgia Street
Vancouver, B.C
V6C 3E8

Website: www.protoxtherapeutics.com

Email: dswetlow@protoxtherapeutics.com

Head Office Telephone Number: (604) 688-0199

Fax Number: (604) 688-0173

Investors Relations: James Beesley
Director, Investor Relations
Tel: (604) 688-0199
Email: jbeesley@protoxtherapeutics.com

Michael Moore
Equicom Group
Tel: (416) 815-0700 x 241
Email: mmoore@equicomgroup.com

Chief Financial Officer: David Swetlow

Corporate Secretary: Iain Mant

Incorporation: The Company was formed on May 20, 2003 under the predecessor to the Business Corporations Act (British Columbia) by the amalgamation of Stratos Biotechnologies Inc., Nucleus BioScience Inc. and Brightwave Ventures Inc. under the name SNB Capital Corp. as a capital pool company pursuant to the policies of the TSX Venture Exchange. Pursuant to a plan of arrangement completed on July 9, 2004, the Company acquired all of the outstanding shares of Protox Pharmaceuticals Inc. ("Protox Pharma") and changed its name to "Protox Therapeutics Inc.". Protox Pharma was incorporated on January 11, 2002.

Fiscal Year End: December 31

Nature of Business: The Company uses genetic engineering to transform naturally occurring proteins into novel targeted therapeutics for the treatment of various cancers and other proliferative diseases. The Company is advancing a pipeline of clinical-stage product candidates and its lead drugs currently in clinical development include PRX321 for primary brain cancer and PRX302 for the treatment of localized prostate cancer and benign prostatic hyperplasia (BPH, commonly known as enlarged prostate).

Transfer Agent & Registrar: Pacific Corporate Trust Company at its principal office in Vancouver and Pacific Corporate Services Ltd. as co-transfer agent at its principal office in Toronto.

Dividends: The Company has not paid any dividends or made any distributions since incorporation. The Company does not anticipate paying dividends in the foreseeable future.